**Strong IPO momentum through late 2026, driven by a crowded pipeline of scheduled listings and recent pricings, underpins high trader confidence in additional offerings before year-end.** Multiple U.S. biotech and tech deals are slated for mid-October, including Iambic Therapeutics (IAM) targeting $150 million around October 15 and City Therapeutics (CTY) around October 16, following recent pricings such as Retension Pharmaceuticals and TRex Bio in early October. Broader activity includes SPAC issuances and international listings, with 2026 year-to-date proceeds already exceeding prior-year totals despite selectivity tied to elevated Treasury yields near 5% and post-Fed rate adjustments. Key catalysts ahead include potential mega-deals like Anthropic’s targeted November listing and further S-1 filings, though macro volatility or weak aftermarket performance could delay marginal candidates. Market-implied odds reflect this active calendar and sustained equity risk appetite.